United States

Analyst Research Report Snapshot


Ark Therapeutics Group plc (AKT) - Financial and Strategic SWOT Analysis Review






12 Oct 2012





Companies referenced:


Available for Immediate Download

Ark Therapeutics Group plc (AKT) - Financial and Strategic SWOT Analysis Review Summary Ark Therapeutics Group plc (Ark Therapeutics) is a UK based specialist healthcare group involved in the discovery, development and commercialization of specialist medicines with focus on vascular disease and cancer. The company’s pipeline product candidates include EG013 for fetal growth restriction, EG011 for refractory angina, EG016 for peripheral vascular disease, Cerepro for malignant glioma, and Trinam for maintaining vascular access grafts. The company operates in the UK and Finland. Ark Therapeutics Group plc Key Recent Developments: Aug 14, 2012: Ark Therapeutics Signs Letter Of Intent With EMD Millipore Corporation Jul 25, 2012: Ark Therapeutics Enters Manufacturing Partnership With European Gene Therapy Company Jul 05, 2012: Ark Therapeutics Appoints David Venables As CEO Apr 25, 2012: Ark Therapeutics's New Manufacturing Suite Receives GMP Approval Mar 13, 2012: Ark Therapeutics Appoints Charles Spicer As Non-Executive Director This comprehensive SWOT profile of Ark Therapeutics Group plc provides you an in-depth strategic analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description - A detailed description of the company's operations and business divisions. - Corporate strategy - Analyst's summarization of the company's business strategy. - SWOT Analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities - A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Key benefits of buying this profile include: You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors. Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.